Mark Looney, MD

Professor
Department of Medicine
Department of Laboratory Medicine
+1 415 476-9190
Research Description: 

Mark R. Looney, MD is a Professor of Medicine and Laboratory Medicine and Attending Physician on the Pulmonary Consult Service and the Intensive Care Units at UCSF. He received his undergraduate degree from Lipscomb University in Nashville, Tennessee in 1994 and his medical degree from the University of Tennessee, Memphis in 1998. He then came to UCSF where he completed his residency in Internal Medicine, a fellowship in Pulmonary and Critical Care Medicine, and research training in the Cardiovascular Research Institute.

Research Interests

My lab is broadly focused on innate immune biology in the lung. Thematic areas include neutrophil and platelet biology as applied to a variety of pulmonary disease states including acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), primary graft dysfunction after lung transplantation, and cystic fibrosis. A major interest is the application of multiphoton intravital lung microscopy as a discovery tool to aid in the study of lung biology, including novel studies on the role of the pulmonary circulation in platelet biogenesis and the hematopoietic potential of the lung. Our overall goal is to identify new mechanisms responsible for lung inflammation and injury and to develop novel therapies to combat lung disease.

Primary Thematic Area: 
Tissue / Organ Biology & Endocrinology
Secondary Thematic Area: 
Immunology
Research Summary: 
Mechanisms of lung inflammation and injury

Websites

Publications: 

Chewing the fat on TRALI.

Blood

Cleary SJ, Looney MR

ß2M Signals Monocytes Through Non-Canonical TGFß Receptor Signal Transduction.

Circulation research

Hilt ZT, Maurya P, Tesoro L, Pariser DN, Ture SK, Cleary SJ, Looney MR, McGrath K, Morrell C

Global absence and targeting of protective immune states in severe COVID-19.

Nature

Combes AJ, Courau T, Kuhn NF, Hu KH, Ray A, Chen WS, Chew NW, Cleary SJ, Kushnoor D, Reeder GC, Shen A, Tsui J, Hiam-Galvez KJ, Muñoz-Sandoval P, Zhu WS, Lee DS, Sun Y, You R, Magnen M, Rodriguez L, Im KW, Serwas NK, Leligdowicz A, Zamecnik CR, Loudermilk RP, Wilson MR, Ye CJ, Fragiadakis GK, Looney MR, Chan V, Ward A, Carrillo S

Lung megakaryocytes are immune modulatory cells.

The Journal of clinical investigation

Pariser DN, Hilt ZT, Ture SK, Blick-Nitko SK, Looney MR, Cleary SJ, Roman-Pagan E, Saunders Ii J, Georas SN, Veazey JM, Madere F, Tesoro Santos L, Arne AM, Huynh NP, Livada AC, Guerrero-Martin SM, Lyons CE, Metcalf Pate KA, McGrath KE, Palis J, Morrell C

Natural killer cells activated through NKG2D mediate lung ischemia-reperfusion injury.

The Journal of clinical investigation

Calabrese DR, Aminian E, Mallavia B, Liu F, Cleary SJ, Aguilar OA, Wang P, Hoover J, Singer JP, Hays SR, Golden JA, Kukreja J, Dugger DT, Nakamura M, Lanier LL, Looney MR, Greenland JR